Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: Extension to describe performance of solid dosage forms

Journal of Pharmaceutical Sciences

Volumn 101, Issue 3, 2012, Pages 1267-1280

  Thelen, Kirstin ^a,b   Coboeken, Katrin ^b   Willmann, Stefan ^b   Dressman, Jennifer B ^a   Lippert, Jörg ^b  

^a GOETHE UNIVERSITY   (Germany)

^b BAYER AG   (Germany)

Author keywords

Absorption; Computational ADME; Dissolution; Dosage forms; Gastrointestinal tract; Modeling; PBPK; Pharmacokinetics; Prediction; Simulation

Indexed keywords

ACICLOVIR; CAFFEINE; CIMETIDINE; DICLOFENAC; DRUG; EUDRAGIT; FUROSEMIDE; PARACETAMOL; PHENOBARBITAL; THEOPHYLLINE;

ARTICLE; CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG SOLUBILITY; ENTERIC COATED TABLET; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRANSIT; HUMAN; IN VITRO STUDY; NORMAL HUMAN; SIMULATION; STOMACH EMPTYING; TABLET;

EID: 84855870739     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22825     Document Type: Article

References (52)

1. Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J. 2010. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, Part I: Oral solutions. J Pharm Sci 100:5324-5345.
2. Bayer Technology Services GmbH. 2009. User manual PK-Sim. 4.2. Leverkusen, Germany: Bayer Technology Services GmbH.
3. Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W. 2003. PK-Sim: A physiologically based pharmacokinetic 'whole-body' model. Biosilico 1:121-124.
4. Willmann S, Lippert J, Schmitt W. 2005. From physicochemistry to absorption and distribution: Predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol 1:159-168.
5. Willmann S, Höhn K, Edginton AN, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. 2007. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 34:401-431.
6. Dressman JB, Amidon GL, Reppas C, Shah VP. 1998. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res 15:11-22.
7. Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB. 1998. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 15:698-705.
8. Jantratid E, De MV, Ronda E, Mattavelli V, Vertzoni M, Dressman JB. 2009. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. Eur J Pharm Sci 37:434-441.
9. Nicolaides E, Galia E, Efthymiopoulos C, Dressman JB, Reppas C. 1999. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm Res 16:1876-1882.
10. Cardot J, Beyssac E, Alric M. 2007. In vitro - in vivo correlation: Importance of dissolution in IVIVC. Dissolution Technol 14:15-19.
11. Costa P, Sousa Lobo JM. 2001. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13:123-133.
12. Bechgaard H. 1982. Design of controlled release products as adapted to gastrointestinal pH and transit time. Acta Pharm Technol 28:149-157.
13. Bechgaard H, Nielsen GH. 1978. Controlled release multiple units and single unit doses: A literature review. Drug Dev Ind Pharm 4:53-67.
14. Follonier N, Doelker E. 1992. Biopharmaceutical comparison of oral multiple-unit and single-unit sustained-release dosage forms. S T P Pharma Sci 2:141-158.
15. Wilding IR, Coupe AJ, Davis SS. 2001. The role of gamma-scintigraphy in oral drug delivery. Adv Drug Deliv Rev 46:103-124.
16. Davis SS, Hardy JG, Fara JW. 1986. Transit of pharmaceutical dosage forms through the small intestine. Gut 27:886-892.
17. Davis SS, Hardy JG, Newman SP, Wilding IR. 1992. Gamma scintigraphy in the evaluation of pharmaceutical dosage forms. Eur J Nucl Med 19:971-986.
18. Kaus LC, Fell JT, Sharma H, Taylor DC. 1984. On the intestinal transit of a single non-disintegrating object. Int J Pharm 20:315-323.
19. Park HM, Chernish SM, Rosenek BD, Brunelle RL, Hargrove B, Wellman HN. 1984. Gastric emptying of enteric-coated tablets. Dig Dis Sci 29:207-212.
20. Podczeck F, Course NC, Newton JM, Short MB. 2007. The influence of non-disintegrating tablet dimensions and density on their gastric emptying in fasted volunteers. J Pharm Pharmacol 59:23-27.
21. Sciarretta G, Furno A, Mazzoni M, Ferrieri A, Malaguti P. 1993. Scintigraphic study of gastrointestinal transit and disintegration sites of mesalazine tablets labeled with technetium-99m. Scand J Gastroenterol 28:783-785.
22. Dilger U. 1996. Gastrointestinaler Transit einer definierten Testmahlzeit durch Magen, Dünndarm und Dickdarm bei chronischem Alkoholabusus, Ph.D. Thesis. Germany: Universitätsklinik der Ruhr-Universität Bochum.
23. Kim SK. 1968. Small intestine transit time in the normal small bowel study. Am J Roentgenol Radium Ther Nucl Med 104:522-524.
24. Wilding IR. 1999. A scintigraphic study to evaluate what happens to Pentasa and Asacol in the human gut. Pract Gastroenterol 23:1-8.
25. Ashford M, Fell JT, Attwood D, Sharma H, Woodhead PJ. 1993. An in vivo investigation into the suitability of pH dependent polymers for colonic targeting. Int J Pharm 95:193-199.
26. Wilding II, Hirst P, Connor A. 2000. Development of a new engineering-based capsule for human drug absorption studies. Pharm Sci Technol Today 3:385-392.
27. Langenbucher F. 1972. Linearization of dissolution rate curves by the Weibull distribution. J Pharm Pharmacol 24:979-981.
28. Goldsmith JA, Randall N, Ross SD. 1978. On methods of expressing dissolution rate data. J Pharm Pharmacol 30:347-349.
29. Schmitt W, Willmann S. 2005. Physiology-based pharmacokinetic modelling: Ready to be used. Drug Discov Today Technol 2:125-132.
30. Palma-Aguirre JA, Absalon-Reyes JA, Novoa-Heckel G, de Lago A, Oliva I, Rodriguez Z, González-de la Parra M, Burke-Fraga V, Namur S. 2007. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: Two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects. Clin Ther 29:1146-1152.
31. Amini H, Javan M, Gazerani P, Ghaffari A, Ahmadiani A. 2008. Lack of bioequivalence between two aciclovir tablets in healthy subjects. Clin Drug Invest 28:47-53.
32. Bott C, Rudolph MW, Schneider AR, Schirrmacher S, Skalsky B, Petereit HU, Langguth P, Dressman JB, Stein J. 2004. In vivo evaluation of a novel pH- and time-based multiunit colonic drug delivery system. Aliment Pharmacol Ther 20:347-353.
33. Klein S, Rudolph MW, Skalsky B, Petereit HU, Dressman JB. 2008. Use of the BioDis to generate a physiologically relevant IVIVC. J Control Release 130:216-219.
34. Jantratid E, Prakongpan S, Amidon GL, Dressman JB. 2006. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: Cimetidine. Clin Pharmacokinet 45:385-399.
35. Lötsch J, Kettenmann B, Renner B, Drover D, Brune K, Geisslinger G, Kobal G. 2000. Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: Relation to pharmacodynamics in an experimental pain model. Pharm Res 17:77-84.
36. Van Gelderen ME, Olling M, Barends DM, Meulenbelt J, Salomons P, Rauws AG. 1994. The bioavailability of diclofenac from enteric coated products in healthy volunteers with normal and artificially decreased gastric acidity. Biopharm Drug Dispos 15:775-788.
37. Awad R, Arafat T, Saket M, Saleh M, Gharaibeh M, Zmeili S, Sallam E, Shubair M, Qobrosi S. 1992. A bioequivalence study of two products of furosemide tablets. Int J Clin Pharmacol Ther Toxicol 30:18-23.
38. Dalton JT, Straughn AB, Dickason DA, Grandolfi GP. 2001. Predictive ability of level A In Vitro - in vivo correlation for ringcap controlled-release acetaminophen tablets. Pharm Res 18:1729-1734.
39. Meyer MC, Straughn AB, Raghow G, Schary WL, Rotenberg KS. 1984. Absorption of phenobarbital from tablets and elixir. J Pharm Sci 73:485-488.
40. Henrist D, Lefebvre RA, Remon JP. 1999. Bioavailability of starch based hot stage extrusion formulations. Int J Pharm 187:185-191.
41. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, Jarvenpaa KM. 1990. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res 7:756-761.
42. Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH. 1989. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther 3:605-613.
43. Fallingborg J. 1999. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull 46:183-196.
44. Kararli TT. 1995. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16:351-380.
45. Idkaidek NM, Amidon GL, Smith DE, Najib NM, Hassan MM. 1998. Determination of the population pharmacokinetic parameters of sustained-release and enteric-coated oral formulations, and the suppository formulation of diclofenac sodium by simultaneous data fitting using NONMEM. Biopharm Drug Dispos 19:169-174.
46. Devarakonda B, Otto DP, Judefeind A, Hill RA, de Villiers MM. 2007. Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes. Int J Pharm 345:142-153.
47. Granero GE, Longhi MR, Mora MJ, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Furosemide. J Pharm Sci 99:2544-2556.
48. Jouyban-Gharamaleki A, Dastmalchi S, Chan HK, Hanaee J, Javanmard A, Barzegar-Jalali M. 2001. Solubility prediction for furosemide in water-cosolvent mixtures using the minimum number of experiments. Drug Dev Ind Pharm 27:577-583.
49. Prasad VK, Rapaka RS, Knight PW, Cabana BE. 1982. Dissolution medium-A critical parameter to identify bioavailability problems of furosemide tablets. Int J Pharm 11:81-90.
50. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
51. Chvasta TE, Cooke AR. 1971. Emptying and absorption of caffeine from the human stomach. Gastroenterology 61:838-843.
52. Willmann S, Edginton AN, Kleine-Besten M, Jantratid E, Thelen K, Dressman JB. 2009. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: Inter-individual variability of cimetidine absorption. J Pharm Pharmacol 61:891-899.